摘要
【目的】探讨依达拉奉对急性脑梗死患者血清神经元特异性烯醇化酶(NSE)、S-100β蛋白的影响及临床疗效。【方法】70例急性脑梗死患者随机分为两组,每组35例。常规治疗相同,其中治疗组给予依达拉奉30 mg静滴,2次/d,7 d为1个疗程,对照组以丹参注射液、胞二磷胆碱静滴,1次/d,7 d为1个疗程。共治疗2个疗程。检测血清中NSE、S-100β的浓度,记录神经功能缺损评分(CSS量表)、评定临床疗效。【结果】两组患者在d1NSE最高,经治疗后逐渐下降,治疗组在d3、d7的NSE浓度明显低于对照组,差异有显著性(P<0.05),两周后NSE下降到相同的水平(P>0.05)。两组患者S-100β在d3达到峰值,其后逐渐降低;治疗组的d3的S-100β水平明显低于对照组,差异有显著性(P<0.05),两周后S-100β下降到相同的水平(P>0.05)。治疗d14后两组CSS评分指数较治疗前均明显减少,治疗组评分少于对照组(P<0.05)。d14时依达拉奉组神经功能改善的总有效率为65.71%,对照组为37.14%。【结论】依达拉奉可降低急性脑梗死患者NSE、S-100β水平,对急性脑梗死的神经元有保护作用,能有效改善急性脑梗死患者的神经功能缺损。
[Objective]To investigate the effect of edaravone on the levels of neuron-specific enolase（NSE）and S-100β in patients with acute ischemic cerebral infarct.[Methods] Seventy patients with acute ischemic cerebral infarct were randomly divided and assigned to the therapy group and the control group.The control group was given a routine treatment of acute ischemic stroke.The therapy group was treated with edaravone in addition to the routine treatment received by the control group.NSE and S-100β concentrations in serum were measured by ELISA.Neurological deficit of two groups were scored for clinical effect assessment.[Results]The level of NSE was deceased gradually after t edaravone treatment for 3 days and 7 days,and the level of NSE of the therapy group was lower significantly than that of control group（P〈0.05）.At 3rd day,the level of S-100β of therapy group was decreased significantly（P〈0.05）.The scores of CSS of two groups improved after 14-day treatment,and the score of CSS of the therapy group was better than that of the control group（P〈0.05）.The efficiency rate was 65.71% in edaravone treating group and 37.14% in routine therapy group at 14th day.[Conclusion]Edaravone injection can decrease the levels of NSE and S-100β,and protect brain tissue from acute cerebral infarction,and lessen nerve function impairment.
出处
《医学临床研究》
CAS
2008年第11期2001-2003,共3页
Journal of Clinical Research
